Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $60 from $45 and keeps a Buy rating on the shares. The firm, which has “high confidence” in the approaching Phase 3 SELVA readout of QTORIN rapamycin in microcystic lymphatic malformations, sees Palvella with “full capacity” to complete mLM development, advance in cutaneous venous malformations, and announce two new indications from the QTORIN platform
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Completes Enrollment in Phase 3 SELVA Trial
- Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)
- Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls
- Palvella Therapeutics initiated with an Outperform at Raymond James
- Innovative QTORIN Platform and Promising Pipeline Drive Buy Rating for Palvella Therapeutics